Search Results | Litt's Drug Eruption and Reaction Database

(2024): Bălăceanu-Gurău B+, Cureus 16(11), e72878
(2019): Yalici-Armagan B+, Cutan Ocul Toxicol Apr, Epub ahead of print
(2018): Sanmartin O, Curr Probl Dermatol 53, 93
(2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
(2016): Clabbers JM+, Support Care Cancer 24(2), 513
(2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 54727% [REVIEW]
(2012): Hello M+, Rev Med Interne (French) 33(5), 273
(2011): Wu PA+, Curr Opin Oncol 23(4), 343 [REVIEW]

Photosensitivity

(2017): Lugovic-Mihic L+, Acta Clin Croat 56(2), 277 [REVIEW]

Pigmentation (Skin) (includes hyperpigmentation)

Pruritus (itching)

(2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
(2016): Clabbers JM+, Support Care Cancer 24(2), 51317%
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2011): Wu PA+, Curr Opin Oncol 23(4), 343 [REVIEW]

Rash

(2024): Lai X+, Medicine (Baltimore) 103(23), e38277 [REVIEW] (association)
(2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
(2017): Chan DLH+, Cochrane Database Syst Rev 6, CD007047 [REVIEW]
(2016): Berger MD+, Expert Opin Drug Saf 15(6), 799 [REVIEW]
(2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
(2014): Hirsh V+, Curr Oncol 21(6), 329
(2014): Vaubel J+, J Eur Acad Dermatol Venereol 28(12), 1685

Rash

(2021): Shi X+, Front Oncol May (e-Collection) [REVIEW]

Telangiectases

Xerosis / xeroderma

(2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
(2018): Sanmartin O, Curr Probl Dermatol 53, 93
(2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
(2016): Clabbers JM+, Support Care Cancer 24(2), 51322%
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 54753% [REVIEW]
(2012): Requena C+, Cutis 90(2), 77
(2012): Thaler J+, BMC Cancer 12, 438
(2011): Wu PA+, Curr Opin Oncol 23(4), 343 [REVIEW]

Alopecia / hair loss

(2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]

Curly hair

(2015): Herink C+, Hautarzt (German) 66(8), 617 (passim)

Hair changes

(2018): Sanmartin O, Curr Probl Dermatol 53, 93
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2011): Wu PA+, Curr Opin Oncol 23(4), 343 [REVIEW]

Nail changes

(2012): Garden BC+, J Am Acad Dermatol 67(3), 400 [REVIEW]
(2011): Wu PA+, Curr Opin Oncol 23 (4), 343

Nail disorder

(2014): Prescrire Int 23(151), 180
(2012): Requena C+, Cutis 90(2), 77

Paronychia

(2022): Liu HL+, J Oncol Pharm Pract Sep, Online ahead of print (22 cases)
(2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
(2018): Sanmartin O, Curr Probl Dermatol 53, 93
(2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
(2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 5475% [REVIEW]
(2015): Melosky B+, Curr Oncol 22(2), 123
(2012): Hello M+, Rev Med Interne (French) 33(5), 273
(2012): Thaler J+, BMC Cancer 12, 438

Pyogenic granuloma

Mucositis

(2024): An Z+, Laryngoscope Investig Otolaryngol 9(3), e1279 (grade 3–4) [REVIEW]
(2017): Vigarios E+, Support Care Cancer 25(5), 1713 [REVIEW]
(2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
(2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 5477% [REVIEW]

Nasal vestibulitis

(2015): Ruiz JN+, Support Care Cancer 23(8), 2391 [REVIEW]

Oral ulceration

(2024): An Z+, Laryngoscope Investig Otolaryngol 9(3), e1279 (grade 3–4) [REVIEW]

Stomatitis (oral mucositis)

(2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
(2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
(2015): Melosky B+, Curr Oncol 22(2), 123

Cardiotoxicity

(2024): Wang Y+, Front Oncol Jun (e-Collection) [REVIEW]

Hypomagnesemia

(2021): Zhang L+, BMJ Open 11(3), e046352 [REVIEW]
(2016): Berger MD+, Expert Opin Drug Saf 15(6), 799 [REVIEW]
(2016): Jiang DM+, Clin Colorectal Cancer 15(3), e117 [REVIEW]

Diarrhea

(2024): Lai X+, Medicine (Baltimore) 103(23), e38277 [REVIEW] (association)
(2023): Cárdenas-Fernández D+, Ther Adv Med Oncol Aug (e-Collection) [REVIEW]
(2021): Shi X+, Front Oncol May (e-Collection) [REVIEW]
(2021): Zhang L+, BMJ Open 11(3), e046352 [REVIEW]
(2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
(2017): Chan DLH+, Cochrane Database Syst Rev 6, CD007047 [REVIEW]
(2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
(2014): Hirsh V+, Curr Oncol 21(6), 329

Gastrointestinal adverse reaction

(2023): Zhang P+, Therap Adv Gastroenterol Apr (e-Collection) [REVIEW]

Vaginal bleeding

(2022): Yu M+, Front Oncol Jun (e-Collection) 69% (abnormal menstruation)

Myelosuppression / bone marrow suppression / myelotoxicity

(2021): Zhang L+, BMJ Open 11(3), e046352 [REVIEW]

Ocular adverse effect

(2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]

Trichomegaly

(2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 5472% [REVIEW]
(2012): Thaler J+, BMC Cancer 12, 438

Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury

(2017): Izzedine H+, Nephrol Dial Transplant 32(7), 1089

Interstitial lung disease / interstitial pneumonitis / interstitial pneumonia (cryptogenic organizing pneumonia) / drug-induced interstitial lung disease

(2023): Kashizaki F+, Clin Lung Cancer Oct, Online ahead of print14% [REVIEW]

Nasopharyngeal necrosis

(2024): An Z+, Laryngoscope Investig Otolaryngol 9(3), e1279 (grade 3–4) (Reported as an adverse reaction event for patients with nasopharyngeal carcinoma following radiotherapy)

Pneumothorax

(2020): Guo R+, Thorac Cancer 11(7), 2031-2035 (3 cases) (with microwave ablation)

Pulmonary toxicity

(2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
(2014): Johkoh T+, Clin Lung Cancer 15(6), 448

Adverse effects / adverse reactions

(2024): An Z+, Laryngoscope Investig Otolaryngol 9(3), e1279 (grade 3–4) [REVIEW]
(2023): Liao D+, Int Immunopharmacol Feb, Online ahead of print (with immune checkpoint inhibitor)
(2020): Huang J+, Sci Rep 10(1), 4803 [REVIEW]
(2020): Zhou JY+, Expert Opin Drug Saf Apr, Epub ahead of print [REVIEW]
(2019): Zhao Y+, BMJ 367, 15460 [REVIEW]
(2017): Below J+, Hautarzt (German) 68(1), 12 [REVIEW] (cutaneous)
(2015): Sharma A+, Perspect Clin Res 6(2), 1091%

Infection

(2024): Lai X+, Medicine (Baltimore) 103(23), e38277 [REVIEW] (association)

Drugs belonging to restart save

class – Epidermal growth factor receptor (EGFR) inhibitor / antagonist – 12 items found

Adverse reactions attributed to entire drug class 'Epidermal growth factor receptor (EGFR) inhibitor / antagonist'